Clinical Trial Detail

NCT ID NCT02990416
Title A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Angimmune LLC
Indications

melanoma

Therapies

A-dmDT390-bisFv(UCHT1) + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.